Details for Patent: 8,579,865
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
Which drugs does patent 8,579,865 protect, and when does it expire?
Patent 8,579,865 protects OTREXUP and is included in one NDA.
This patent has twelve patent family members in seven countries.
Summary for Patent: 8,579,865
| Title: | Hazardous agent injection system |
| Abstract: | Injection systems comprising a powered injector and one or more hazardous agents are disclosed. |
| Inventor(s): | Wotton; Paul (Stamford, CT), Sadowski; Peter L. (Woodbury, MN), Hayes; John William (Chaska, MN) |
| Assignee: | Antares Pharma, Inc. (Ewing, NJ) |
| Application Number: | 13/257,555 |
|
Patent Claim Types: see list of patent claims | Dosage form; Use; |
Drugs Protected by US Patent 8,579,865
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Otter Pharms | OTREXUP | methotrexate | SOLUTION;SUBCUTANEOUS | 204824-005 | Nov 7, 2014 | DISCN | Yes | No | See Plans and Pricing | See Plans and Pricing | Y | SUBCUTANEOUS INJECTION OF METHOTREXATE | See Plans and Pricing | |||
| Otter Pharms | OTREXUP | methotrexate | SOLUTION;SUBCUTANEOUS | 204824-001 | Oct 11, 2013 | RX | Yes | Yes | See Plans and Pricing | See Plans and Pricing | Y | SUBCUTANEOUS INJECTION OF METHOTREXATE | See Plans and Pricing | |||
| Otter Pharms | OTREXUP | methotrexate | SOLUTION;SUBCUTANEOUS | 204824-006 | Mar 24, 2016 | RX | Yes | Yes | See Plans and Pricing | See Plans and Pricing | Y | SUBCUTANEOUS INJECTION OF METHOTREXATE | See Plans and Pricing | |||
| Otter Pharms | OTREXUP | methotrexate | SOLUTION;SUBCUTANEOUS | 204824-002 | Oct 11, 2013 | RX | Yes | Yes | See Plans and Pricing | See Plans and Pricing | Y | SUBCUTANEOUS INJECTION OF METHOTREXATE | See Plans and Pricing | |||
| Otter Pharms | OTREXUP | methotrexate | SOLUTION;SUBCUTANEOUS | 204824-007 | Mar 24, 2016 | RX | Yes | Yes | See Plans and Pricing | See Plans and Pricing | Y | SUBCUTANEOUS INJECTION OF METHOTREXATE | See Plans and Pricing | |||
| Otter Pharms | OTREXUP | methotrexate | SOLUTION;SUBCUTANEOUS | 204824-003 | Oct 11, 2013 | RX | Yes | Yes | See Plans and Pricing | See Plans and Pricing | Y | SUBCUTANEOUS INJECTION OF METHOTREXATE | See Plans and Pricing | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
Foreign Priority and PCT Information for Patent: 8,579,865
| PCT Information | |||
| PCT Filed | March 19, 2010 | PCT Application Number: | PCT/US2010/028011 |
| PCT Publication Date: | September 23, 2010 | PCT Publication Number: | WO2010/108116 |
International Family Members for US Patent 8,579,865
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Australia | 2010226442 | See Plans and Pricing | |||
| Canada | 2755779 | See Plans and Pricing | |||
| China | 102612381 | See Plans and Pricing | |||
| European Patent Office | 2408493 | See Plans and Pricing | |||
| Japan | 2012521224 | See Plans and Pricing | |||
| Japan | 2015042270 | See Plans and Pricing | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
